Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAYHIA: Phase 3 randomized double-blind ianalumab vs placebo in warm autoimmune hemolytic anemia
jRCT2031220601Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in warm autoimmune hemolytic anemia (wAIHA) (3 arms), sponsored by Novartis. Primary endpoint: Durable hemoglobin response. Started Jul 2023; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on jRCT2031220601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220601.